Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board

• Round led by Swedish investor Flerie Invest AB with substantial contributions from the Netherlands Enterprise Agency and existing shareholders
• Appoints a new Supervisory Board with six highly experienced individuals
• Start of first-in-man phase I/II clinical study of its SV40-based gene delivery vector platform named SVac expected in two to three years

LEIDEN, the Netherlands, October 16, 2019-- Amarna Therapeutics, a privately held biotechnology company developing a next-generation SV40-based gene delivery vector platform named SVac that promises to transform …